History
| 1957 |
Established the Minami Nihon Dog Center (with an animal hospital) in Kagoshima City
|
|---|---|
| 1960 | Began offering safety testing (preclinical studies) as Japan's first contract research organization for pharmaceutical development |
| 1974 | Changed the company name to SNBL |
| 1980 | Established a new Safety Research Institute in Yoshida Town, Kagoshima District (now Miyanojo-cho, Kagoshima City), and relocated the head office accordingly |
| 1982 | Successfully built the world's first online computer system in preparation for the enforcement of GLP (Good Laboratory Practice) standards for non-clinical safety studies of pharmaceuticals |
| 1983 | Obtained GLP compliance (the first CRO in Japan) from the Ministry of Health, Labour and Welfare, and began safety studies. Expanded the research building |
| 1986 | Constructed a breeding facility for laboratory NHPs in Indonesia |
| 1988 | Established a U.S. branch office in Maryland as a business base in the United States |
| 1989 | Started breeding laboratory NHPs in China in collaboration with local companies |
| 1991 |
Spun off the U.S. branch as SNBL U.S.A., Ltd. Built a clinical pharmacology trial facility (CPC Clinic) in Kagoshima City |
| 1993 | Launched contract services for clinical pharmacology and Phase I clinical trials |
| 1997 | Established a Translational Research (TR) business division |
| 1998 | Opened a Drug Metabolism Analysis Center in Kainan City, Wakayama Prefecture, and began offering analysis and pharmacokinetic study services |
| 1999 |
Started contract services for Phase II and Phase III clinical trials Relocated SNBL U.S.A., Ltd. to Everett, a suburb of Seattle, and established a new non-clinical testing facility 
|
| 2000 | SNBL U.S.A., Ltd.: Obtained AAALAC International accreditation |
| 2003 | Constructed a breeding facility for laboratory NHPs in Guangdong Province, China |
| 2004 |
Listed on the Tokyo Stock Exchange Mothers Market Built a clinical pharmacology trial facility on the campus of the University of Maryland in Baltimore, USA |
| 2005 | Medipolis business launched |
| 2007 | Constructed a breeding facility for laboratory NHPs in Cambodia |
| 2008 | Transferred to the First Section of the Tokyo Stock Exchange |
| 2011 | Safety Research Institute: Obtained AAALAC International accreditation |
| 2015 |
Wave Life Sciences, a company established by us in 2012 for nucleic acid drug development, was listed on the NASDAQ in the United States Established the joint venture SNBL PPD |
| 2019 | Satsuma Pharmaceuticals, a company established by us in 2016, was listed on the NASDAQ in the United States |
| 2022 |
Transitioned to the Prime Market, the new market segment of the Tokyo Stock Exchange Made Inari Research Co., Ltd. a consolidated subsidiary |
| 2023 | Made Satsuma Pharmaceuticals a consolidated subsidiary |
| 2024 |
Established a new research building at the Kagoshima headquarters
|